1.86

4.49% 0.08

Skye Bioscience Inc (SKYE)

Overview News Price History Discussions Forecast

Skye Bioscience Inc stock is traded at $1.86, with a volume of 182.85K. It is up +4.49% in the last 24 hours and up +223.48% over the past month. Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Previous Close:

$1.78

Open:

$1.77

24h Volume:

182.85K

Relative Volume:

0.48

Market Cap:

$65.88M

Revenue:

Net Income/Loss:

$-57.33M

P/E Ratio:

-1.287

EPS:

-1.4452

Net Cash Flow:

$-42.44M

1W Performance:

+4.79%

1M Performance:

+223.48%

6M Performance:

+151.15%

1Y Performance:

-50.40%

1-Day Range:

$1.77

$1.95

1-Week Range:

$1.64

$2.05

52-Week Range:

$0.255

$4.9902

Skye Bioscience Inc Stock (SKYE) Company Profile

Name

Skye Bioscience Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(858) 410-0266

Address

11250 EL CAMINO REAL, SUITE 100, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-20

Latest SEC Filings

SKYE's Discussions on Twitter

Compare SKYE vs PSNYW, GOODO, SHMD, DWLD, QQQE

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SKYE Skye Bioscience Inc.	3.10	12.89M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	5.00	394.14M	2.07B	-1.42B	-1.37B	-0.6765
GOODO Gladstone Commercial Corporation	20.92	372.90M	0	0	0	0.00
SHMD Schmid Group N V	3.15	315.90M	52.15M	-21.46M	0	-0.4675
DWLD Davis Select Worldwide ETF	47.39	0	0	0	0	0.00
QQQE Direxion NASDAQ-100 Equal Weigh	120.75	0	0	0	0	0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-06-25	Downgrade	Craig Hallum	Buy → Hold
Aug-15-25	Initiated	Evercore ISI	Outperform
Feb-28-25	Initiated	William Blair	Outperform
Sep-30-24	Initiated	Scotiabank	Sector Outperform
Sep-10-24	Initiated	JMP Securities	Mkt Outperform
Jul-09-24	Initiated	Craig Hallum	Buy
May-23-24	Initiated	Cantor Fitzgerald	Overweight
Apr-12-24	Initiated	Oppenheimer	Outperform

View All

Skye Bioscience Inc Stock (SKYE) Latest News

Aug 20, 2026

Skye Bioscience director Andrew Schwab sells $140,313 in stock By Investing.com - Investing.com India

Aug 20, 2026

Skye Bioscience director Andrew Schwab sells $140,313 in stock - Investing.com

Aug 20, 2026

5am Partners VII, LLC sells $140,313 of Skye Bioscience stock - Investing.com

Aug 20, 2026

Skye Bioscience (SKYE) insider funds sell 375,840 shares at $0.32–$0.41 - Stock Titan

Aug 20, 2026

Skye Bioscience (SKYE) 5AM funds sell at penny-level prices - Stock Titan

Aug 20, 2026

Aug 19, 2026

Skye Bioscience, Inc. Common Stock (NASDAQ: SKYE) Share Price, SKYE Stock News, SKYE Share Price & Updates - Kalkine

Aug 19, 2026

Form 8K Skye Bioscience Inc For: 19 August By Investing.com - Investing.com South Africa

Aug 19, 2026

Skye Bioscience flags Nasdaq noncompliance after stockholders’ equity falls to ($497,307) - Bitget

Aug 19, 2026